IONS Ionis Pharmaceuticals Inc.

58.76
+1.35  (+2%)
Previous Close 57.41
Open 57.52
Price To Book 11.37
Market Cap 8083701928
Shares 137,571,510
Volume 413,957
Short Ratio
Av. Daily Volume 841,471

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
Phase 2 top-line data due 2019.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 2 data presented at AHA November 2018 - endpoints met.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2b data due mid-2019.
IONIS-FXIRx
End-stage renal disease
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.
Phase 1/2 data possibly due early 2019.
IONIS-SOD1Rx
Amyotrophic lateral sclerosis (ALS)
Phase 2 trial to be initiated early 2019.
IONIS-FB-LRx
Geographic Atrophy (GA)
Phase 1b/2 data presented at ESMO 2018. 23% PR/CR.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer